Replicate Bioscience Shares New Preclinical srRNA Data at American Association for Cancer Research Annual Meeting 2023

Poster presentations provide data on Replicate’s lead immuno-oncology candidate, RBI-1000, in targeting acquired resistance mutations and on another proof-of-concept study demonstrating the potential of Replicate’s novel srRNA technology for protein drug replacement SAN DIEGO, March 14,…

Click here to view original post